Parminder Singh, MD
Internal Medicine · Marion, OHNPI 1598756546
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 309 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 309 payments — averaging $23.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ZOLL Respicardia, Inc.$845
- AstraZeneca$782
- Pfizer$486
- Veryan Medical Incorporated$457
- Boston Scientific$455
- plus $3K from 33 others
Across 269 payments — averaging $2555.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$296K
- AstraZeneca$156K
- Boehringer Ingelheim Pharma GmbH & Co.kg$129K
- Amgen$60K
- Alnylam Pharmaceuticals Inc.$43K
- Regeneron$2K
- plus $2K from 1 others
What the payments were for
- Food & beverage$7,164100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 67 | $1,148 |
| ZOLL Respicardia, Inc. | 2 | $845 |
| AstraZeneca | 34 | $782 |
| Pfizer | 49 | $486 |
| Veryan Medical Incorporated | 3 | $457 |
| Boston Scientific | 5 | $455 |
| Lilly USA, LLC | 23 | $434 |
| Novo Nordisk | 26 | $370 |
| Insulet Corporation | 8 | $276 |
| GSK | 18 | $272 |
| Corvista Health, Inc. | 2 | $216 |
| Corcept Therapeutics | 7 | $124 |
| Johnson & Johnson | 8 | $122 |
| Exact Sciences | 6 | $107 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $102 |
| Amgen | 5 | $102 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $97 |
| Astellas Pharma US Inc | 6 | $91 |
| Medicomp Inc | 3 | $81 |
| Abbott | 1 | $73 |
| Otsuka America Pharmaceutical, Inc. | 4 | $66 |
| Avanos Medical | 1 | $57 |
| Lundbeck LLC | 2 | $51 |
| Vanda Pharmaceuticals Inc. | 2 | $48 |
| Sanofi-aventis U.S. LLC | 3 | $40 |
| Novartis | 2 | $36 |
| Cardiva Medical, Inc. | 1 | $28 |
| Lifescan, Inc. | 1 | $26 |
| Indivior Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $17 |
| Chiesi USA, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| UCB, Inc. | 1 | $14 |
| Ascensia Diabetes Care US Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Merck | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- remede System$845
- BioMimics$457
- CorVista System$151
- BodyGuardian$147
- CDS broad portfolio offering$139
- WALLSTENT RP Endoprosthesis$138
- AIRSUPRA$128
- BREZTRI$121
- COLOGUARD$120
How this compares
$7,168 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,199 | $489,260 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 37 | $279,352 |
| XifaxanRifaximin | 116 | $221,857 |
| TrulicityDulaglutide | 179 | $178,712 |
| OzempicSemaglutide | 131 | $158,328 |
| Everolimus | 13 | $155,038 |
| MyrbetriqMirabegron | 508 | $128,199 |
| JanuviaSitagliptin Phosphate | 175 | $104,713 |
| XareltoRivaroxaban | 250 | $101,942 |
| FarxigaDapagliflozin Propanediol | 189 | $71,991 |
| Invega SustennaPaliperidone Palmitate | 22 | $66,731 |
| JardianceEmpagliflozin | 128 | $58,388 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 237 | $56,481 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $54,842 |
| RexultiBrexpiprazole | 62 | $51,106 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $486 | $510,0021,265 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $15 | $279,35237 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $102 | $221,857116 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $434 | $215,291200 claims |
| Johnson & JohnsonXarelto, Invega Sustenna, Risperdal Consta | $122 | $192,482284 claims |
| Novo NordiskOzempic, Rybelsus | $370 | $174,072145 claims |
| Astellas Pharma US IncMyrbetriq | $91 | $128,199508 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $782 | $119,174273 claims |
| MerckJanuvia | $14 | $104,713175 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $272 | $86,399141 claims |
| AbbVieLinzess, Vraylar | $1,148 | $69,856108 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $66 | $51,10662 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Marion
- Arthur ArmstrongMarion$44K
- Hassan MalikAkron$1.7M
- Cyrus HarrisCleveland$726K
- Nina DeepWesterville$614K
- Necklall KhooblallAustintown$448K
- Daniel WeissMentor$406K
- Richard KimDayton$326K
- Marina MagreyCleveland$312K
- Lisa LarkinCincinnati$276K
- Gregg FaimanMayfield Hts$274K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.